Fractyl Health grants 845,226 stock options at $2.24 to officer

Fractyl Health, Inc. reported that one of its officers, serving as President and Chief Product Officer, received a stock option grant on 12/15/2025.

Rhea-AI Filing Summary

Fractyl Health, Inc. reported that one of its officers, serving as President and Chief Product Officer, received a stock option grant on 12/15/2025. The option covers 845,226 shares of common stock at an exercise price of $2.24 per share and expires on 12/14/2035.

According to the disclosure, the option vests and becomes exercisable in equal installments on each of the first three anniversaries of the grant date, as long as the officer remains employed through each vesting date. Following this grant, the officer beneficially owns 845,226 derivative securities, held directly.

Insider Trade Summary

Grant/Award: 845,226 shares

Grant/Award 1 txn

Insider Caplan Jay David

Role President, Chief Product Off.

Type	Security	Shares	Price	Value
Grant/Award	Stock Option (right to buy)	845,226	$0.00	$0.00

Holdings After Transaction: Stock Option (right to buy) — 845,226 contracts (Direct)

Footnotes (1)

1. F1. The stock option vests and becomes exercisable in equal installments on each of the first three anniversaries of the grant date, subject to the Reporting Persons's continuing in employment through each such vesting date.

FAQ

AI-generated questions and answers. How Rhea-AI works. Not financial advice.

What insider transaction did Fractyl Health (GUTS) report in this Form 4?

The company reported a stock option grant to an officer, covering 845,226 shares of Fractyl Health, Inc. common stock as a derivative security.

What is the exercise price of the options granted at Fractyl Health (GUTS)?

The stock option has an exercise price of $2.24 per share for the underlying common stock.

When was the Fractyl Health (GUTS) stock option grant made and when does it expire?

The option grant date is 12/15/2025, and the option expires on 12/14/2035.

How do the Fractyl Health (GUTS) options vest for this officer?

The stock option vests in equal installments on each of the first three anniversaries of the 12/15/2025 grant date, subject to the officer continuing in employment through each vesting date.

What role does the reporting person hold at Fractyl Health (GUTS)?

The reporting person is an officer of Fractyl Health, Inc., serving as President, Chief Product Officer.

How many derivative securities does the Fractyl Health (GUTS) officer own after the transaction?

After this reported transaction, the officer beneficially owns 845,226 derivative securities (stock options), held directly.

AI-generated analysis. How Rhea-AI works. Not financial advice.

Form 4 Insider Transactions: What Each Field Means →

See more from StockTitan in Google Search and AI answers. Adds StockTitan as a preferred source · opens Google

Add on Google Not now

Accepted by SEC EDGAR 12/17/2025 - 06:00 PM Learn about SEC filing dates

SEC Form 4

FORM 4

UNITED STATES SECURITIES AND EXCHANGE COMMISSION
Washington, D.C. 20549

STATEMENT OF CHANGES IN BENEFICIAL OWNERSHIP

Filed pursuant to Section 16(a) of the Securities Exchange Act of 1934
or Section 30(h) of the Investment Company Act of 1940

OMB APPROVAL

OMB Number:			3235-0287
Estimated average burden
hours per response:			0.5

Check this box if no longer subject to Section 16. Form 4 or Form 5 obligations may continue. See Instruction 1(b).

Check this box to indicate that a transaction was made pursuant to a contract, instruction or written plan for the purchase or sale of equity securities of the issuer that is intended to satisfy the affirmative defense conditions of Rule 10b5-1(c). See Instruction 10.

1. Name and Address of Reporting Person^*

Caplan Jay David

(Last) (First) (Middle)

3 VAN DE GRAAFF DRIVE

SUITE 200

(Street)

BURLINGTON MA 01803

(City) (State) (Zip)

2. Issuer Name and Ticker or Trading Symbol
FRACTYL HEALTH, INC. [ GUTS ]

5. Relationship of Reporting Person(s) to Issuer
(Check all applicable)

	Director		10% Owner
X	Officer (give title below)		Other (specify below)
	President, Chief Product Off.

3. Date of Earliest Transaction (Month/Day/Year)
12/15/2025

4. If Amendment, Date of Original Filed (Month/Day/Year)

6. Individual or Joint/Group Filing (Check Applicable Line)

X	Form filed by One Reporting Person
	Form filed by More than One Reporting Person

Table I - Non-Derivative Securities Acquired, Disposed of, or Beneficially Owned
1. Title of Security (Instr. 3)	2. Transaction Date (Month/Day/Year)	2A. Deemed Execution Date, if any (Month/Day/Year)	3. Transaction Code (Instr. 8)		4. Securities Acquired (A) or Disposed Of (D) (Instr. 3, 4 and 5)			5. Amount of Securities Beneficially Owned Following Reported Transaction(s) (Instr. 3 and 4)	6. Ownership Form: Direct (D) or Indirect (I) (Instr. 4)	7. Nature of Indirect Beneficial Ownership (Instr. 4)
			Code	V	Amount	(A) or (D)	Price

Table II - Derivative Securities Acquired, Disposed of, or Beneficially Owned (e.g., puts, calls, warrants, options, convertible securities)
1. Title of Derivative Security (Instr. 3)	2. Conversion or Exercise Price of Derivative Security	3. Transaction Date (Month/Day/Year)	3A. Deemed Execution Date, if any (Month/Day/Year)	4. Transaction Code (Instr. 8)		5. Number of Derivative Securities Acquired (A) or Disposed of (D) (Instr. 3, 4 and 5)		6. Date Exercisable and Expiration Date (Month/Day/Year)		7. Title and Amount of Securities Underlying Derivative Security (Instr. 3 and 4)		8. Price of Derivative Security (Instr. 5)	9. Number of derivative Securities Beneficially Owned Following Reported Transaction(s) (Instr. 4)	10. Ownership Form: Direct (D) or Indirect (I) (Instr. 4)	11. Nature of Indirect Beneficial Ownership (Instr. 4)
				Code	V	(A)	(D)	Date Exercisable	Expiration Date	Title	Amount or Number of Shares
Stock Option (right to buy)	$2.24	12/15/2025		A		845,226		(1)	12/14/2035	Common Stock	845,226	$0	845,226	D

Explanation of Responses:

1. The stock option vests and becomes exercisable in equal installments on each of the first three anniversaries of the grant date, subject to the Reporting Persons's continuing in employment through each such vesting date.

	/s/ Harith Rajagopalan, Attorney-in-fact	12/17/2025
	** Signature of Reporting Person	Date
Reminder: Report on a separate line for each class of securities beneficially owned directly or indirectly.
* If the form is filed by more than one reporting person, see Instruction 4 (b)(v).
** Intentional misstatements or omissions of facts constitute Federal Criminal Violations See 18 U.S.C. 1001 and 15 U.S.C. 78ff(a).
Note: File three copies of this Form, one of which must be manually signed. If space is insufficient, see Instruction 6 for procedure.
Persons who respond to the collection of information contained in this form are not required to respond unless the form displays a currently valid OMB Number.